-+ 0.00%
-+ 0.00%
-+ 0.00%

Piper Sandler Reiterates Overweight on Biogen, Raises Price Target to $305

Benzinga·11/09/2026 17:08:08
Listen to the news
Piper Sandler analyst David Amsellem reiterates Biogen (NASDAQ:BIIB) with a Overweight and raises the price target from $245 to $305.